Magnite: Cash Flows Now Matter (NASDAQ:MGNI)

Gladiathor I previously suggested that Magnite, Inc.’s (NASDAQ:MGNI) strong cash flows would eventually matter, and this has proven to be the case over the past three months, with the stock up around 40%. While the business continues to face headwinds, and competition remains a threat, Magnite’s growth is starting to pick up and its margins…

Read More

Earnings Will Matter In 2024

Daniel Grizelj It’s the last trading day in 2023, and it’s fair to say that the year turned out better than most of the pundits had predicted. Now, of course, the pundits are busy with their prognostications for the year ahead, including specific calls for US equities and other asset classes that will likely reach…

Read More

Amicus Therapeutics: Limited Label For Pombiliti And Opfolda, Why It May Not Matter (FOLD)

Olivier Le Moal Shares of Amicus Therapeutics (NASDAQ:FOLD) declined after the company announced the FDA approval of Pombiliti and Opfolda (which was called AT-GAA), which is the third treatment approved for the treatment of late-onset Pompe disease. The decline was most likely driven by a worse-than-expected label that says only patients who are not improving…

Read More

Polygon Zero Accuses Matter Labs’ Developers of Copying Source Code

While Polygon Zero is claiming the code was used without the original copyrights or clear attribution to the original authors, Matter Labs stated that the code was “prominently attributed” in a line atop one of the files in question. Polygon and Matter Labs continue their competition on building zero-knowledge rollups. Polygon’s unit Polygon Zero, which is standing behind a layer…

Read More